John Mendlein, Director at FATE THERAPEUTICS INC (FATE), sold 1,364 shares at $22.79 ($31K) on 2022-06-03, disclosed to the SEC on 2022-06-06.
Open-market sale of $31k FATE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| LIFE | BUY | 2018-12-26 | $102K | — | Filing → |
| LIFE | BUY | 2017-09-05 | $200K | — | Filing → |
| LIFE | BUY | 2017-04-26 | $372 | — | Filing → |